# Boundless Bio, Inc.: overview

BOLD · Nasdaq · CIK 1782303 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/bold.md) · [Financials](/companies/bold/financials.md) · [Filings](/companies/bold/filings.md) · [Insiders](/companies/bold/insiders.md)

Revenue is not reported in this company’s XBRL financial statements.

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Diluted EPS | $ per share | [(0.74)](/filings/0001193125-25-265714.md) | not reported | [(0.71)](/filings/0001193125-26-213321.md) | [(0.70)](/filings/0001193125-26-339093.md) | [(0.62)](/filings/0001193125-25-265714.md) | not reported | [(0.60)](/filings/0001193125-26-213321.md) | [(1.06)](/filings/0001193125-26-339093.md) |
| Free cash flow | $m | [(13.7) d](/filings/0001193125-25-265714.md) | [(16.0) d](/filings/0001193125-26-097543.md) | [(14.6)](/filings/0001193125-26-213321.md) | [(11.9) d](/filings/0001193125-26-339093.md) | [(10.2) d](/filings/0001193125-25-265714.md) | [(10.5) d](/filings/0001193125-26-097543.md) | [(15.0)](/filings/0001193125-26-213321.md) | [(21.0) d](/filings/0001193125-26-339093.md) |

- Revenue. XBRL not reported.
- Gross margin (gross profit / revenue). XBRL not reported.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported |
| Gross margin | % | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | not reported |
| Net margin | % | not reported | not reported | not reported |
| Diluted EPS | $ per share | [(40.65)](/filings/0000950170-25-045725.md) | [(3.85)](/filings/0001193125-26-097543.md) | [(2.60)](/filings/0001193125-26-097543.md) |
| Free cash flow | $m | [(47.5)](/filings/0000950170-25-045725.md) | [(63.4)](/filings/0001193125-26-097543.md) | [(47.2)](/filings/0001193125-26-097543.md) |

- Revenue. XBRL not reported.
- Gross margin (gross profit / revenue). XBRL not reported.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/bold/insiders.md)

| Date | Insider | Role | Transaction | Shares | Reported price | Value | Filing |
| --- | --- | --- | --- | ---: | ---: | ---: | --- |
| 2026-10-26 | [Tang Kevin](/insiders/1178579.md) | 10% owner | Purchase (P) | 9,606 | $2.38 | $22.9k | [Form 4](/filings/0001178579-26-000020.md) |
| 2026-10-23 | [Tang Kevin](/insiders/1178579.md) | 10% owner | Purchase (P) | 6,234 | $2.38 | $14.8k | [Form 4](/filings/0001178579-26-000020.md) |
| 2026-10-22 | [Tang Kevin](/insiders/1178579.md) | 10% owner | Purchase (P) | 5,800 | $2.40 | $13.9k | [Form 4](/filings/0001178579-26-000020.md) |

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [ARCH Venture Management, LLC](/funds/1274403.md) | 2026-06-30 | $6.7m | 2,694,095 |  | New +2,694,095 |
| [FMR LLC](/funds/315066.md) | 2026-06-30 | $6.5m | 2,581,055 |  | Reduced −114,400 |
| [TANG CAPITAL MANAGEMENT LLC](/funds/1232621.md) | 2026-06-30 | $6.4m | 2,559,875 |  | New +2,559,875 |
| [ADAR1 Capital Management, LLC](/funds/1940272.md) | 2026-06-30 | $4.9m | 1,968,216 |  | New +1,968,216 |
| [Cormorant Asset Management, LP](/funds/1583977.md) | 2026-06-30 | $2.5m | 1,000,000 |  | New +1,000,000 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $1.5m | 614,923 |  | Added +17,731 |
| [WELLINGTON MANAGEMENT GROUP LLP](/funds/902219.md) | 2026-06-30 | $1.4m | 556,233 |  | Unchanged |
| [MILLENNIUM MANAGEMENT LLC](/funds/1273087.md) | 2026-06-30 | $1.2m | 478,639 |  | Added +378,764 |
| [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $1.2m | 471,570 |  | Added +72,570 |
| [Alyeska Investment Group, L.P.](/funds/1453072.md) | 2026-06-30 | $750.0k | 300,000 |  | Unchanged |

## Recent filings

[All 157 filings](/companies/bold/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-08-28 | 17:25 ET | [8-K](/filings/0001193125-26-374787.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001193125-26-374787 |
| 2026-08-07 | 07:00 ET | [10-Q](/filings/0001193125-26-339093.md) | Quarterly report, period 2026-06-30 | 0001193125-26-339093 |
| 2026-06-23 | 08:30 ET | [8-K](/filings/0001193125-26-278570.md) | 1.01 Entry into a material agreement; 2.05 Exit or disposal costs; 3.02 Unregistered sale of equity; 5.01 Change in control; 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-278570 |
| 2026-06-17 | 10:49 ET | [8-K](/filings/0001193125-26-273544.md) | 5.07 Shareholder vote results | 0001193125-26-273544 |
| 2026-05-08 | 07:10 ET | [10-Q](/filings/0001193125-26-213321.md) | Quarterly report, period 2026-03-31 | 0001193125-26-213321 |
| 2026-05-08 | 07:05 ET | [8-K](/filings/0001193125-26-213269.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-213269 |
| 2026-04-28 | 16:00 ET | [DEF 14A](/filings/0001193125-26-186884.md) | Proxy statement, period 2026-06-15 | 0001193125-26-186884 |
| 2026-04-13 | 17:15 ET | [8-K](/filings/0001193125-26-153076.md) | 1.02 Termination of a material agreement; 2.03 New direct financial obligation | 0001193125-26-153076 |
| 2026-03-09 | 07:10 ET | [10-K](/filings/0001193125-26-097543.md) | Annual report, period 2025-12-31 | 0001193125-26-097543 |
| 2026-03-09 | 07:05 ET | [8-K](/filings/0001193125-26-097535.md) | 2.02 Results of operations; 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001193125-26-097535 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-097543.md), filed Mar 9, 2026.

## Forecast league

Not in this season’s league. [This season’s league](/leagues.md)

## About the filer

- CIK: 1782303
- Tickers: BOLD
- Exchange: Nasdaq
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: DE
- Filer category: Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 18:21 ET. No prices; not investment advice.